Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics(clinical),General Medicine
Reference115 articles.
1. Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. J Pediatr. 1980;97(2):332–3.
2. New measures to avoid valproate exposure in pregnancy endorsed. European Medicines Agency. 2018: EMA/145600/2018 Available from.
https://www.ema.europa.eu/documents/referral/valproate-article-31-referral-new-measures-avoid-valproate-exposure-pregnancy-endorsed_en-0.pdf
. Accessed 31 May 2018.
3. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–26.
4. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. 1982;2:1282–3.
5. Robert E, Rosa F. Valproate and birth defects. Lancet. 1983;2(8359):1142.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献